Selecting GLP-1 Agonists in the Management of Type 2 Diabetes: Differential Pharmacology and Therapeutic Benefits of Liraglutide and Exenatide

Therapeutics and Clinical Risk Management
doi 10.2147/tcrm.s7313
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Informa UK Limited

Related search

Pdb68 - Cost-Effectiveness Analysis of Exenatide Versus GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Role and Development of GLP-1 Receptor Agonists in the Management of Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2009English

SGLT2 Inhibitors or GLP-1 Receptor Agonists as Second-Line Therapy in Type 2 Diabetes: Patient Selection and Perspectives

Vascular Health and Risk Management
2016English

Correction To: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features

Clinical Drug Investigation
MedicinePharmacology
2020English

Evaluating Preferences for Profiles of GLP-1 Receptor Agonists Among Injection-Naïve Type 2 Diabetes Patients in the UK

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2015English

Management of Type 2 Diabetes Mellitus: Selecting the Right of Antihyperglycemic Medication

Medical Council
2018English

Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?

Open Journal of Endocrine and Metabolic Diseases
2016English

Correction To: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults With Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

Advances in Therapy
MedicinePharmacology
2019English

Semaglutide: A New GLP‐1 Analogue for Type 2 Diabetes

Prescriber
Pharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy